Post-COVID-19 deep vein thrombosis and its pharmacological management
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
DOI: | 10.33448/rsd-v11i1.24991 |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/24991 |
Resumo: | Infection caused by the SARS-CoV-2 coronavirus presents clinical cases that range from asymptomatic to severe. Even in milder cases, sequelae related to a hypercoagulable state associated with COVID-19 can be observed, with an increased prevalence of Venous Thromboembolism (VTE). The occurrence of VTE is higher in patients, mainly patients hospitalized in intensive care units and requires anticoagulation therapy, however, post-COVID thrombogenesis can also occur at a later stage, in the absence of viral load. The prothrombotic mechanisms related to SARS-CoV-2 differ with regard to the use of antiplatelet and anticoagulant drugs in patients with suspected or confirmed COVID-19. The pharmacology and clinical applicability of anticoagulant drugs such as heparins and oral anticoagulants will be described in this study. This study is an exploratory study aiming to address issues related to the treatment hitherto recommended for thrombotic events in patients affected by COVID-19. |
id |
UNIFEI_00ad4aad524fdec905ac72ab8cb0097a |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/24991 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
spelling |
Post-COVID-19 deep vein thrombosis and its pharmacological managementTrombosis venosa profunda post-COVID-19 y su manejo farmacológicoA trombose venosa profunda pós-COVID-19 e seu manejo farmacológicoSARS-CoV-2COVID-19AnticoagulantsVenous thromboembolism.SARS-CoV-2COVID-19AnticoagulantesTromboembolia venosa.SARS-CoV-2COVID-19AnticoagulantesTromboembolia venosa.Infection caused by the SARS-CoV-2 coronavirus presents clinical cases that range from asymptomatic to severe. Even in milder cases, sequelae related to a hypercoagulable state associated with COVID-19 can be observed, with an increased prevalence of Venous Thromboembolism (VTE). The occurrence of VTE is higher in patients, mainly patients hospitalized in intensive care units and requires anticoagulation therapy, however, post-COVID thrombogenesis can also occur at a later stage, in the absence of viral load. The prothrombotic mechanisms related to SARS-CoV-2 differ with regard to the use of antiplatelet and anticoagulant drugs in patients with suspected or confirmed COVID-19. The pharmacology and clinical applicability of anticoagulant drugs such as heparins and oral anticoagulants will be described in this study. This study is an exploratory study aiming to address issues related to the treatment hitherto recommended for thrombotic events in patients affected by COVID-19.La infección causada por el coronavirus SARS-CoV-2 presenta casos clínicos que van desde asintomáticos hasta graves. Incluso en casos leves, se pueden observar secuelas relacionadas con un estado de hipercoagulabilidad asociado a COVID-19, con una mayor prevalencia de tromboembolismo venoso (TEV). La aparición de TEV es mayor en pacientes, principalmente pacientes hospitalizados en unidades de cuidados intensivos y requiere tratamiento anticoagulante, sin embargo, la trombogénesis post-COVID también puede ocurrir en una etapa posterior, en ausencia de carga viral. Los mecanismos protrombóticos relacionados con el SARS-CoV-2 difieren con respecto al uso de fármacos antiplaquetarios y anticoagulantes en pacientes con COVID-19 sospechado o confirmado. En este estudio se describirán la farmacología y la aplicabilidad clínica de los fármacos anticoagulantes como las heparinas y los anticoagulantes orales. Este estudio es un estudio exploratorio que tiene como objetivo abordar cuestiones relacionadas con el tratamiento hasta ahora recomendado para eventos trombóticos en pacientes afectados por COVID-19.A infecção causada pelo coronavírus SARS-CoV-2 apresenta casos clínicos que variam de assintomáticos para graves. Mesmo nos casos mais brandos, podem ser observadas sequelas relacionadas a um estado hipercoagulável associado à COVID-19, com a prevalência aumentada de Tromboembolismo Venoso (TEV). A ocorrência de TEV é maior principalmente em pacientes internados em unidades de terapia intensiva e requer terapia de anticoagulação, no entanto, a trombogênse pós-COVID também pode ocorrer numa fase mais tardia, na ausência de carga viral. Os mecanismos pró-trombóticos relacionados ao SARS-CoV-2 apresentam divergências no que se refere ao uso de medicamentos antiplaquetários e anticoagulantes em pacientes com suspeita ou confirmação de COVID-19. A farmacologia e a aplicabilidade clínica dos fármacos anticoagulantes como as heparinas e os anticoagulantes orais, serão descritas neste estudo. Este estudo é um estudo exploratório com o objetivo de abordar as questões relacionadas ao tratamento farmacológico e os mecanismos de ação dos fármacos até então recomendados para o tratamento e profilaxia dos eventos trombóticos em pacientes acometidos pela COVID-19.Research, Society and Development2022-01-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2499110.33448/rsd-v11i1.24991Research, Society and Development; Vol. 11 No. 1; e12311124991Research, Society and Development; Vol. 11 Núm. 1; e12311124991Research, Society and Development; v. 11 n. 1; e123111249912525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/24991/21733Copyright (c) 2022 Clara Maria Muguet; Karoline Guimarães; Lilian Bastos; Marcela Baroni; Marcela Curty; Marcos Marzano; Mariana Costa; Mirela Tardelli; Rafael Risi ; Renata Lustosa ; Vanessa Estatohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMuguet, Clara Maria Guimarães, KarolineBastos, Lilian Baroni, Marcela Curty, MarcelaMarzano, MarcosCosta, MarianaTardelli, Mirela Risi , Rafael Lustosa , RenataEstato, Vanessa 2022-01-16T18:08:18Zoai:ojs.pkp.sfu.ca:article/24991Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:43:22.858692Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Post-COVID-19 deep vein thrombosis and its pharmacological management Trombosis venosa profunda post-COVID-19 y su manejo farmacológico A trombose venosa profunda pós-COVID-19 e seu manejo farmacológico |
title |
Post-COVID-19 deep vein thrombosis and its pharmacological management |
spellingShingle |
Post-COVID-19 deep vein thrombosis and its pharmacological management Post-COVID-19 deep vein thrombosis and its pharmacological management Muguet, Clara Maria SARS-CoV-2 COVID-19 Anticoagulants Venous thromboembolism. SARS-CoV-2 COVID-19 Anticoagulantes Tromboembolia venosa. SARS-CoV-2 COVID-19 Anticoagulantes Tromboembolia venosa. Muguet, Clara Maria SARS-CoV-2 COVID-19 Anticoagulants Venous thromboembolism. SARS-CoV-2 COVID-19 Anticoagulantes Tromboembolia venosa. SARS-CoV-2 COVID-19 Anticoagulantes Tromboembolia venosa. |
title_short |
Post-COVID-19 deep vein thrombosis and its pharmacological management |
title_full |
Post-COVID-19 deep vein thrombosis and its pharmacological management |
title_fullStr |
Post-COVID-19 deep vein thrombosis and its pharmacological management Post-COVID-19 deep vein thrombosis and its pharmacological management |
title_full_unstemmed |
Post-COVID-19 deep vein thrombosis and its pharmacological management Post-COVID-19 deep vein thrombosis and its pharmacological management |
title_sort |
Post-COVID-19 deep vein thrombosis and its pharmacological management |
author |
Muguet, Clara Maria |
author_facet |
Muguet, Clara Maria Muguet, Clara Maria Guimarães, Karoline Bastos, Lilian Baroni, Marcela Curty, Marcela Marzano, Marcos Costa, Mariana Tardelli, Mirela Risi , Rafael Lustosa , Renata Estato, Vanessa Guimarães, Karoline Bastos, Lilian Baroni, Marcela Curty, Marcela Marzano, Marcos Costa, Mariana Tardelli, Mirela Risi , Rafael Lustosa , Renata Estato, Vanessa |
author_role |
author |
author2 |
Guimarães, Karoline Bastos, Lilian Baroni, Marcela Curty, Marcela Marzano, Marcos Costa, Mariana Tardelli, Mirela Risi , Rafael Lustosa , Renata Estato, Vanessa |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Muguet, Clara Maria Guimarães, Karoline Bastos, Lilian Baroni, Marcela Curty, Marcela Marzano, Marcos Costa, Mariana Tardelli, Mirela Risi , Rafael Lustosa , Renata Estato, Vanessa |
dc.subject.por.fl_str_mv |
SARS-CoV-2 COVID-19 Anticoagulants Venous thromboembolism. SARS-CoV-2 COVID-19 Anticoagulantes Tromboembolia venosa. SARS-CoV-2 COVID-19 Anticoagulantes Tromboembolia venosa. |
topic |
SARS-CoV-2 COVID-19 Anticoagulants Venous thromboembolism. SARS-CoV-2 COVID-19 Anticoagulantes Tromboembolia venosa. SARS-CoV-2 COVID-19 Anticoagulantes Tromboembolia venosa. |
description |
Infection caused by the SARS-CoV-2 coronavirus presents clinical cases that range from asymptomatic to severe. Even in milder cases, sequelae related to a hypercoagulable state associated with COVID-19 can be observed, with an increased prevalence of Venous Thromboembolism (VTE). The occurrence of VTE is higher in patients, mainly patients hospitalized in intensive care units and requires anticoagulation therapy, however, post-COVID thrombogenesis can also occur at a later stage, in the absence of viral load. The prothrombotic mechanisms related to SARS-CoV-2 differ with regard to the use of antiplatelet and anticoagulant drugs in patients with suspected or confirmed COVID-19. The pharmacology and clinical applicability of anticoagulant drugs such as heparins and oral anticoagulants will be described in this study. This study is an exploratory study aiming to address issues related to the treatment hitherto recommended for thrombotic events in patients affected by COVID-19. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-01-03 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/24991 10.33448/rsd-v11i1.24991 |
url |
https://rsdjournal.org/index.php/rsd/article/view/24991 |
identifier_str_mv |
10.33448/rsd-v11i1.24991 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/24991/21733 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 1; e12311124991 Research, Society and Development; Vol. 11 Núm. 1; e12311124991 Research, Society and Development; v. 11 n. 1; e12311124991 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1822178477074284544 |
dc.identifier.doi.none.fl_str_mv |
10.33448/rsd-v11i1.24991 |